Safety profile of the fluoroquinolones: Analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy

Drug Safety

Volumn 33, Issue 9, 2010, Pages 789-799

  Lapi, Francesco ^a,b,c   Tuccori, Marco ^a,d   Motola, Domenico ^e   Pugi, Alessandra ^a,b   Vietri, Michele ^a,b   Montanaro, Nicola ^d   Vaccheri, Alberto ^d   Leoni, Olivia ^f   Cocci, Alfredo ^f   Leone, Roberto ^g   Conforti, Anita ^g   Moretti, Ugo ^g   Sessa, Emiliano ^c   Mazzaglia, Giampiero ^c   Mugelli, Alessandro ^a,b   Mazzei, Teresita ^b   Vannacci, Alfredo ^a,b  

^a Tuscan Regional Centre of Pharmacovigilance   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Regional Agency for Healthcare Services of Tuscany   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Lombardy Centre of Pharmacovigilance   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

Author keywords

Ciprofloxacin, adverse reactions; Fluoroquinolones, adverse reactions; Levofloxacin, adverse reaction; Moxifloxacin, adverse reactions; Postmarketing surveillance; Prulifloxacin, adverse reactions.

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PRULIFLOXACIN; QUINOLONE DERIVATIVE;

ACHILLES TENDINITIS; ACHILLES TENDON RUPTURE; ANAPHYLACTIC SHOCK; ARTICLE; CARDIOVASCULAR DISEASE; DATA BASE; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; ERYTHEMA; GASTROINTESTINAL DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; ITALY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TENDINITIS; TENDON RUPTURE; UROGENITAL TRACT DISEASE; URTICARIA;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CHILD; DATABASES, FACTUAL; FEMALE; FLUOROQUINOLONES; HUMANS; ITALY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77955564682     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536810-000000000-00000     Document Type: Article

References (39)

1. Osservatorio Nazionale sull'Impiego dei Medicinali. L'uso deifarmaci in Italia. Rapporto Nazionale. Rome: Direzione Generale della Valutazione dei medicinali e della Farm-acovigilanza, 2004
2. Osservatorio Nazionale sull'Impiego dei Medicinali. L'usodei farmaci in Italia. Rapporto Nazionale. Rome: Direzione Generale della Valutazione dei medicinali e della Farm-acovigilanza, 2005
3. Osservatorio Nazionale sull'Impiego dei Medicinali. L'usodei farmaci in Italia. Rapporto Nazionale. Rome: Direzione Generale della Valutazione dei medicinali e della Farm-acovigilanza, 2006
4. Osservatorio Nazionale sull'Impiego dei Medicinali. L'uso deifarmaci in Italia. Rapporto Nazionale. Rome: Direzione Generale della Valutazione dei medicinali e della Farm-acovigilanza, 2007
5. Mehlhorn AJ, Brown DA. Safety concerns with fluoro-quinolones. Ann Pharmacother 2007; 41 (11): 1859-1866
6. Owens Jr RC, Ambrose PG. Clinical use of the fluoroquin-olones. Med Clin North Am 2000; 84 (6): 1447-1469
7. Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective,comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005; 25 (10): 1303-1309
8. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus onfluoroquinolones. Clin Infect Dis 2005; 41 Suppl. 2: S144-57
9. Leone R, Venegoni M, Motola D, et al. Adverse drug reac-tions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Saf 2003; 26 (2): 109-120
10. Gruppo Interregionale di Farmacovigilanza (GIF) [online].Available from URL: http://www.gruppogif.org [Accessed 2009 Mar 30]
11. Gazzetta Ufficiale della Repubblica Italiana n° 101 03 Maggio2003. Rome: Decreto Legislativo n° 95, 2003 Apr 8Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-2234
12. Rossi M, Lusini G, Biasella A, etal. Prulifloxacin as a triggerof myasthenia gravis. J Neurol Sci 2009; 280 (1-2): 109-110
13. Gallelli L, Gallelli A, Vero G, et al. Acute renal failureprobably induced by prulifloxacin in an elderly woman: a first case report. Clin Drug Investig 2006; 26 (1): 49-53
14. Pierfitte C, Begaud B, Lagnaoui R, et al. Is reporting rate agood predictor of risks associated with drugs? Br J Clin Pharmacol 1999; 47 (3): 329-331
15. Brown EG. Effects of coding dictionary on signal genera-tion: a consideration of use of MedDRA compared with WHO-ART. Drug Saf 2002; 25 (6): 445-452
16. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharma-covigilance of biopharmaceuticals: challenges remain. Drug Saf 2009; 32 (10): 811-817
17. WHO technical report no. 498, 1972 [online]. Available fromURL http://www.who-umc.org/DynPage.aspx?id=22676 [Accessed 2006 Dec]
18. Olsson S. The role of the WHO programme on InternationalDrug Monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998; 19 (1): 1-10
19. Weber JCP. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. In: Rainford KD, Velo GP, editors. Advances in information research 6. New York: Raven Press, 1984: 1-7
20. De Graaf L, Fabius MA, Diemont WL, et al. The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles. Pharm World Sci 2003; 25 (6): 260-263
21. Autorizzazione all'immissione in commercio della specialita'medicinale per uso umano )Keraflox*. Decreto A.I.C. n. 310 del 21 giugno 2004. Rome: Gazzetta Ufficiale della Repubblica Italiana, 2004
22. Van Bambeke F, Michot JM, Van Eldere J, et al. Quinolonesin 2005: an update. Clin Microbiol Infect 2005; 11 (4): 256-280
23. Salas M, Hofman A, Stricker BH. Confounding by indica-tion: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149 (11): 981-983
24. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendi-nopathy: a critical review of the literature. Clin Infect Dis 2003; 36 (11): 1404-1410
25. Van Der Linden PD, Sturkenboom MC, Herings RM, et al.Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324 (7349): 1306-1307
26. Van Der Linden PD, Sturkenboom MC, Herings RM, et al.Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163 (15): 1801-1807
27. Ambrose PG, Owens Jr RC, Quintiliani R, et al. New gen-erations of quinolones: with particular attention to levo-floxacin. Conn Med 1997; 61 (5): 269-272
28. Nori S, Nebesio C, Brashear R, et al. Moxifloxacin-associateddrug hypersensitivity syndrome with toxic epidermal ne-crolysis and fulminant hepatic failure. Arch Dermatol 2004; 140 (12): 1537-1538
29. Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of al-lergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf 2007; 30 (8): 705-713
30. Van Bambeke F, Tulkens PM. Safety profile of the respira-tory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32 (5): 359-378
31. Shehab N, Patel PR, Srinivasan A, et al. Emergency de-partment visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47 (6): 735-743
32. Hauben M, Aronson JK. Defining 'signal' and its subtypesin pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32 (2): 99-110
33. Goossens H, Ferech M, Vander SR, et al. Outpatient antibioticuse in Europe and association with resistance: a cross-national database study. Lancet 2005; 365 (9459): 579-587
34. Ferech M, Coenen S, Malhotra-Kumar S, et al. EuropeanSurveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58 (2): 423-427 (Pubitemid 44294958)
35. Coenen S, Ferech M, Haaijer-Ruskamp FM, et al. EuropeanSurveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care 2007; 16 (6): 440-445
36. Elseviers MM, Ferech M, Vander Stichele RH, et al. Antibio-tic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Phar-macoepidemiol Drug Saf 2007; 16 (1): 115-123
37. Goossens H, Ferech M, Coenen S, et al. Comparison of out-patient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007; 44 (8): 1091-1095
38. Vander Stichele RH, Elseviers MM, Ferech M, et al.European surveillance of antimicrobial consumption(ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004; 58 (4): 419-428
39. Tubert-Bitter P, Begaud B, Moride Y, et al. Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. J Clin Epidemiol 1996; 49 (1): 121-123